Terry Fox Laboratory
The Terry Fox Laboratory strives to understand the biology underlying normal development and how its disruption leads to cancer initiation and progression. The creation of new technologies and model systems to address this problem is a hallmark of our departmental culture.
Located in Vancouver, BC
We are a dynamic team of international talents!
Ongoing research across a wide spectrum of biomedicine and the life sciences; including biochemistry, stem cell biology, immunology, molecular genetics, molecular medicine and gene therapy.
The Terry Fox Laboratory (TFL) has expertise in diverse research areas, including mammalian systems, normal and malignant mammary tissues, lineage specification in the gut, and yeast genetics. Experimental approaches employed at TFL include genetically engineered models, patient xenograft models, in vitro cell based assays, highly dimension single cell phenotyping, molecular biology and biochemistry, DNA regulation, transcriptomics, epigenetics, and DNA repair. In recent years, TFL has placed emphasis on the development of new technologies and their use to address fundamental questions in the control of cell growth and differentiation, aging, and gene regulation.
Working with innovative model systems and patients our research addresses the root causes of leukemias and myeloma and is developing new tools for their diagnosis, characterization and treatment.
Genes influence every aspect of human biology and disease. We are studying how our genes and genomes are faithfully maintained as we age and the complex ways in which they are regulated to control development or are dysregulated during cancer formation.
Stem cells are critical components in healthy aging and tumour suppression since they enable the development and maintenance of adult tissues. We are working to understand how stem cell properties enable blood, breast and liver development and how these properties are co-opted in cancers.
Research Labs & Principal Investigators
Dr. Allen Eaves, PhD, FRCPC, FACP
Dr. R. Keith Humphries, MD, PhD, FRS(C)
Dr. Donna Hogge, MD, PhD
Dr. Dixie Mager, PhD
Dr. Ryan Brinkman, PhD
News & Events
Single substitution in H3.3G34 alters DNMT3A recruitment to cause progressive neurodegeneration.
flowCut: An R package for automated removal of outlier events and flagging of files based on time versus fluorescence analysis.
Identifying effect modifiers of CAR-T cell therapeutic efficacy: a systematic review and individual patient data meta-analysis protocol.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.